Libtayo (cemiplimab) shows sustained survival benefit at five years in advanced non-small cell lung cancer

Recent data from WCLC show that Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared with chemotherapy.

The WCLC presentation will also discuss data on overall survival, progression-free survival, and response rate among patients who added chemotherapy to Libtayo after disease progression